Prot# CRAD001NUS65: An Open-label, Single-arm Phase II Study of Everolimus (RAD001) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date3/14/10 → 6/20/15

Funding

  • Novartis Pharmaceuticals Corporation (CRAD001NUS65)